Trametinib, anlotinib, and tislelizumab for KRAS-mutant lung cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer with a KRAS mutation that has spread or come back.
- You've already had one type of standard treatment (like chemo or immunotherapy) and it stopped working.
- You have no active brain tumors that are growing or causing symptoms.
- You are between 18 and 75 years old and have a good ability to do daily activities (ECOG score 0-2).
- Your liver, kidney, and blood cell counts are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
This study tests a new combination of two targeted drugs (andamertinib and anlotinib) for lung cancer that has EGFR mutations and has progressed after a prior EGFR TKI. It aims to see if the combination can shrink tumors and help control the cancer.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
Hear when a new KRAS Mutation-Related Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.